As CGRP-targeted therapies move into wider use, new data are beginning to clarify their role in special populations, the value of switching agents when one fails, and their long-term vascular safety.

Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...

The approval of medicines called “CGRP antagonists” has led to big changes in how migraines are managed. These medicines work in a different way than older medicines to treat or prevent migraine. The ...

A statistically significant reduction in the mean number of monthly headache days (vs baseline) was observed for the CGRP-targeted therapies and propranolol ...

Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...

The approval of medicines called CGRP antagonists has led to big changes in how migraine is managed. These medicines work in a different way than older medicines to treat or prevent migraine. The ...

The first three calcitonin gene-related peptide (CGRP) inhibitors approved for prevention of migraine displayed a reassuring safety profile in real-world clinical practice during the first 6 months ...

Direct calcitonin gene-related peptide with monoclonal antibody exposure was also associated with significantly reduced rates of acne and rosacea compared with topiramate. HealthDay News — For ...

The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the onset of migraines.

Significantly reduced rate of acne and rosacea seen in patients treated with CGRPi mAbs vs triptans, topiramate. HealthDay News — For patients experiencing migraine, direct calcitonin gene-related ...